We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » Impact: FDA User Fees, Drug Competition and Pricing - Webinar CD/Transcript

Other Options

Audio CD/Transcript - June 13, 2017

$287.00

Audio CD/Transcript - June 13, 2017

$258.00

Audio CD/Transcript - June 13, 2017

$244.00

Audio CD/Transcript - June 13, 2017

$230.00

Audio CD/Transcript - June 13, 2017

$215.00

Impact: FDA User Fees, Drug Competition and Pricing - Webinar CD/Transcript

$287.00
Webinar Recordings

Product Details

Impact: FDA User Fees, Drug Competition and Pricing — An Inside View

User fees affect drug competition at every level. And user fees are a hot topic during the current budget cycle.

Even as you read this, top-level meetings are under way at the FDA, the White House and in Congress. Policy is being hammered out amid great uncertainty under a new FDA administrator, Scott Gottlieb and a new White House that boasts no special background in drug policy or regulation.

If you plan to remain competitive, it’s time to get up to speed.

Washington insiders Alex Brill and Nancy Bradish Myers Esq. share insights, make forecasts, and help you deal with a fast-changing regulatory and policy landscape. You’ll gain an understanding of:

  • How the FDA affects drug competition at every level — brand-to-brand, brand-to-generic, generic-to-generic, biologic-to-biosimilar
  • Expedited approvals and economic incentives — how the FDA promotes drug competition
  • Five ways Congress and the FDA can boost competition and the likelihood of each
  • What to expect from the Gottlieb FDA
  • And much more!

The Washington landscape is changing fast. Stay competitive! Discover what you need to know now.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing